Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05537402 · ClinicalTrials.gov registry record · Phase 2
LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT05537402 is a Phase 2 study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 1 participants.
The verdict
NCT05537402, a Phase 2 study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this research study is to compare the effectiveness and safety of two standard of care treatments in people who have been diagnosed with hepatocellular carcinoma (HCC).This research study is being done to compare atezolizumab/bevacizumab to locoregional therapy with either transarterial chemoembolization (TACE) or transarterial radioembolization (TARE).
Interventions
- DRUG Atezolizumab and bevacizumab
- RADIATION transarterial chemoembolization (TACE) or transarterial radioembolization (TARE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-09-27 |
| Est. Completion | 2025-06-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05537402
The ClinicalTrials.gov registry entry for NCT05537402 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atezolizumab and bevacizumab is the first listed.
NCT05537402 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05537402 about?
NCT05537402 is a clinical study titled "LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC". The purpose of this research study is to compare the effectiveness and safety of two standard of care treatments in people who have been diagnosed with hepatocellular carcinoma (HCC).This research study is being done to compare atezolizumab/bevacizumab to locoregional therapy with either transarteri...
What is the current status of trial NCT05537402?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2023-09-27. Estimated completion is 2025-06-06.
What interventions are being tested in trial NCT05537402?
The interventions under investigation include: Atezolizumab and bevacizumab (DRUG), transarterial chemoembolization (TACE) or transarterial radioembolization (TARE (RADIATION).
Who is sponsoring clinical trial NCT05537402?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.